It’s a GlobeImmune kind of day…How exciting to see Dr. Freytag join the GI Board of Directors. Dr. Freytag was President, Chief Executive Officer and Chairman of the Board of Aspreva Pharmaceuticals Company from July 2007 through December 2007 when Aspreva was acquired by Galenica for approximately $915 million. He held the same positions with Myogen, Inc. from July 1998 until November 2006 when Myogen was acquired by Gilead (NASDAQ: GILD) for approximately $2.5 billion. Dr. Freytag currently serves on the Board of Directors for Sierra Neuropharmaceuticals, ARCA Discovery, AlphaSniffer and Immunicon (Nasdaq:IMMC). Dr. Freytag has held senior executive roles in a number of capacities at companies such as Somatogen, a biopharmaceutical company where he was responsible for corporate and commercial development and at Boehringer Mannheim Corporation where he served as President of Research and Development. Dr. Freytag spent 10 years with DuPont Medical Products in various research and business positions. He earned his Ph.D. in biochemistry from the University of Kansas Medical Center.
*NOTE* Feel the power of the Colorado BioScience Association (HERE)!
*NOTE* Take a look at the new Boulder Biotech Company Tree (HERE)!
*NOTE* Read the new eBook CLSDF 2007 - What's In A Year? (HERE)!
If you enjoyed this post get free email or RSS updates (here).